Wanbury Limited reports 11.6% growth in revenue for Q2 FY25, EBITDA surges 19.6%
Wanbury Limited, a leading pharmaceutical company with a global footprint in active pharmaceutical ingredients (APIs) and domestic branded formulations, has announced a stellar financial performance ... Read More
IOL Chemicals and Pharmaceuticals sees revenue growth but faces margin pressure in Q2
IOL Chemicals and Pharmaceuticals Limited (IOLCP), a leader in pharmaceutical active pharmaceutical ingredients (APIs) and specialty chemicals, recently reported its financial performance for Q2 FY25, ... Read More
FDA approves ZITUVIMET by Zydus Lifesciences for Type 2 diabetes treatment
Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and ... Read More
Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ... Read More
Dr. Reddy’s Laboratories debuts generic version of KOMBIGLYZE XR in US
In a significant development for diabetes treatment in the U.S., Dr. Reddy's Laboratories has unveiled its Saxagliptin and Metformin Hydrochloride Extended-Release Tablets. This launch introduces ... Read More
BRENZAVVY proves effective in TheracosBio’s Phase 3 Type 2 diabetes study
TheracosBio announced the publication of a 24-week randomized, double-blind, placebo-controlled trial, proving Bexagliflozin's effectiveness as an adjunct to Metformin for treating adults with type 2 ... Read More
Zydus Lifesciences gets FDA tentative approval for Invokamet generic
Zydus Lifesciences said that its subsidiary Zydus Pharmaceuticals (USA) has been granted tentative approval for Canagliflozin and Metformin Hydrochloride Tablets, 50mg/500mg, 50mg/1,000mg, 150mg/500mg, and 150mg/1,000mg ... Read More
AstraZeneca India scraps Dapagliflozin distribution deal with Abbott
AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in ... Read More